Ferroptosis is an iron-dependent, regulated form of cell death characterized by excessive lipid peroxidation and antioxidant failure. The review authors described a set of core regulators that determine whether cardiomyocytes succumb to this pathway. GPX4 activity—or its loss—was framed as central: glutathione depletion and GPX4 inactivation permit toxic lipid peroxide accumulation. SLC7A11, which controls cystine uptake and glutathione synthesis, was discussed as an upstream node influencing redox balance. The transcription factor NRF2 emerged in the text as a master regulator of antioxidant responses, with effects on several ferroptosis-related genes. Lipid metabolism enzymes, notably ACSL4, were identified for their role in shaping the pool of peroxidation-susceptible phospholipids. Parallel, GPX4-independent systems were reviewed: FSP1 and DHODH were noted as alternative ferroptosis suppressors operating in different cellular compartments. Ferritinophagy and iron handling stood out as determinants of labile iron that feed reactive oxygen species generation. The authors reported interactions between these ferroptosis regulators and other regulated cell-death pathways, indicating mechanistic cross-talk rather than absolute separations.
The review collated evidence that ferroptosis contributes across multiple cardiac disease settings. Investigators reported links to ischemia–reperfusion injury, where reoxygenation and disturbed iron homeostasis favor lipid peroxidation. Anthracycline-induced cardiotoxicity was singled out for its association with ferroptotic mechanisms in cardiomyocytes. Metabolic cardiac disorders, diabetic cardiomyopathy, and progressive heart failure were also discussed as contexts in which ferroptosis may play a meaningful role. The authors stressed that ferroptosis presents a mechanistic axis distinct from apoptosis and necroptosis; because it is driven by lipid peroxidation and glutathione/GPX4 dysfunction, it may offer a reversible therapeutic target in settings where other cell-death pathways dominate.
A range of pharmacologic strategies appears in the review. Small-molecule ferroptosis inhibitors were summarized as one approach to limit lipid peroxidation or restore redox buffering. Natural phytochemicals—compounds derived from plants—were presented in the article as candidate modulators of antioxidant pathways and ferroptosis regulators. The authors outlined that targeting cystine uptake, preserving glutathione levels, stabilizing GPX4, inhibiting ACSL4-mediated pro-oxidant lipid remodeling, or chelating labile iron are mechanistic levers for drug development. The review did not report specific dosing regimens or clinical trial results; it focused instead on mechanism-driven candidate classes and preclinical rationale.
Beyond small molecules and phytochemicals, the authors reviewed gene- and molecular-target approaches. Modulating expression or function of SLC7A11, GPX4, FSP1, or NRF2 was discussed as a theoretical route to reduce cardiomyocyte ferroptosis. The review highlighted nanoparticle-based delivery as a translationally relevant platform to target cardiomyocytes, and it noted the potential of multi-omics integration and artificial intelligence-assisted predictive modeling to refine target selection and patient stratification. The source did not provide clinical trial protocols or human testing outcomes for these delivery or modeling strategies; investigators presented them as prospective translational tools.
The authors critically evaluated challenges to moving ferroptosis-targeted therapies into clinical practice. They stated that there is an absence of validated, ferroptosis-specific biomarkers suitable for human studies, which complicates diagnosis, target engagement assessment, and patient selection. Limited human-relevant disease models—versus the abundant preclinical models—were identified as a gap restricting translational fidelity. Interpatient heterogeneity was named as an additional obstacle: variable iron handling, metabolic states, and comorbidities may affect who benefits from ferroptosis modulation. These limitations were presented as key reasons why clinical translation remains incomplete.
The authors considered the cardio-oncology implications of ferroptosis inhibition. They noted that anthracycline cardiotoxicity is among the settings where ferroptosis-targeted cardioprotection could matter most. At the same time, the review raised the issue that inhibiting ferroptosis might interact with anticancer efficacy—because ferroptotic mechanisms can also contribute to tumor cell death in some contexts. The article therefore framed therapeutic development as requiring careful balance: protect the heart without diminishing antitumor activity. The review did not offer definitive clinical guidance on how to achieve that balance; rather, the authors flagged it as a crucial translational question.
The review lays out several open research priorities that remain unresolved in the literature it surveyed. There is no consensus, authors noted, on validated ferroptosis biomarkers for clinical use. Human-relevant in vitro and in vivo models remain limited relative to preclinical animal studies, reducing confidence in translational predictions. Interpatient biological variability—iron metabolism, redox state, and comorbid disease—was flagged as a source of uncertainty for therapeutic response. The authors also observed unresolved tensions in cardio-oncology regarding potential effects of ferroptosis inhibition on anticancer outcomes. These documented limitations define immediate next steps for researchers and set boundaries for clinical expectations until targeted biomarkers, improved models, and patient-stratification tools are developed.
The article ends with those specific, documented gaps rather than broad generalities: validated biomarkers, human-relevant models, and strategies to manage patient heterogeneity are the tangible translational hurdles the field must address before ferroptosis-targeted cardioprotective therapies can be widely tested in humans.